Company intelligence / Profile preview

Gaorui Yaoye

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Gaorui Pharmaceutical is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the development of innovative small molecule therapies for metabolic diseases. The company focuses on next-generation treatments for type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH) by targeting incretin receptors. Its lead programs include oral small molecule agonists for the GLP-1 receptor, designed to provide more convenient alternatives to injectable biologics. Gaorui aims to address significant unmet medical needs in the metabolic space through rigorous R&D and clinical validation.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

BGC0222

Unknown

Beyond the preview

Go deeper on Gaorui Yaoye.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gaorui Yaoye.

Explore the full profile